HORIZON-HLTH-2021-CORONA-01-01
HORIZON-HLTH-2021-CORONA-01-01
Programme: Horizon Europe
5 projects · €46,735,797 total EU contribution (project-level) · 52 participating organizations · 17 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€46,735,797
Countries active
Participant organizations by country (headquarters in CORDIS).
- Spain (17)
- Germany (9)
- France (4)
- AT (3)
- BE (3)
- Netherlands (3)
- CH (2)
- Italy (2)
- EL (1)
- FI (1)
- IE (1)
- LT (1)
- PT (1)
- RO (1)
- TR (1)
- UK (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- ICS2 projects · ES
- UNIVERSITAIR MEDISCH CENTRUM GRONINGEN1 projects · NL
- AZM1 projects · NL
- accelCH1 projects · CH
- ASPHALION1 projects · ES
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 projects · FR
- BNI1 projects · DE
- PHOX Consulting e.U.1 projects · AT
- Catalyze B.V.1 projects · NL
- DRUG DEVELOPMENT AND REGULATION SL1 projects · ES
- HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS1 projects · EL
- EATG1 projects · DE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Novel, orally available immune modulator MP1032 with anti-SARS-CoV-2 and anti-cytokine activity iMPact · 101046182 | HORIZON | €7,988,724 | €0 | Details |
RBD Dimer recombinant protein vaccine against SARSCoV2 RBDCOV · 101046118 | HORIZON | €9,779,211 | €0 | Details |
Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC EPIC-CROWN-2 · 101046084 | HORIZON | €9,070,134 | €508,376 | Details |
ExeVir's XVR011, a best in class nanobody-based biology that broadly neutralizes SARS-COV-1 and SARS-COV-2 XVR011 Phase 2 · 101045949 | HORIZON | €9,902,750 | €2,592,750 | Details |
Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19 COVend · 101045956 | HORIZON | €9,994,978 | €81,263 | Details |